SAI PARENTERALS LIMITED (SAIPARENT) financials
SAI PARENTERALS LIMITED (SAIPARENT) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
- Market Cap: ₹2,153Cr.
- Current Price: ₹487
- Stock P/E: 86.7
- ROE: 5.80%
- ROCE: 7.03%
- Book Value: ₹
- Dividend Yield: 0.00%
- 52W High / Low: ₹706/400
In Jun 2026, SAI PARENTERALS LIMITED (SAIPARENT) reported sales ₹52.78 Cr and net profit ₹8.88 Cr.
Annual Mar 2026: sales ₹166 Cr, net profit ₹17 Cr.
Shareholding: Promoters 51.16% (Sep 2026), FIIs 2.85% (Sep 2026), DIIs 7.83% (Sep 2026), Public 38.16% (Sep 2026), No. of Shareholders 13,645% (Sep 2026).
| Category | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 19.20 | 38.48 | 56.79 | 52.78 |
| Expenses | 16.17 | 34.51 | 43.56 | 39.43 |
| Operating Profit | 3.03 | 3.97 | 13.23 | 13.35 |
| OPM % | 15.78% | 10.32% | 23.30% | 25.29% |
| Other Income | 1.24 | 0.75 | 0.12 | 3.41 |
| Interest | 1.76 | 2.12 | 3.42 | 3.57 |
| Depreciation | 1.32 | 1.60 | 1.53 | 1.36 |
| Profit before tax | 1.19 | 1.00 | 8.40 | 11.83 |
| Tax % | 30.25% | 64.00% | -18.45% | 24.94% |
| Net Profit | 0.83 | 0.36 | 9.95 | 8.88 |
| EPS in Rs | 0.30 | 0.10 | 2.25 | 2.01 |
| Raw PDF | — | — | — | — |
| Category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 97 | 114 | 127 | 166 |
| Expenses | 79 | 92 | 100 | 137 |
| Operating Profit | 18 | 21 | 27 | 28 |
| OPM % | 18% | 19% | 21% | 17% |
| Other Income | 0 | 1 | 0 | 5 |
| Interest | 5 | 6 | 7 | 9 |
| Depreciation | 6 | 6 | 5 | 6 |
| Profit before tax | 7 | 10 | 14 | 19 |
| Tax % | 37% | 30% | 28% | 11% |
| Net Profit | 5 | 7 | 10 | 17 |
| EPS in Rs | 3.22 | 2.70 | 3.86 | 3.80 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 7 | 13 | 13 | 22 |
| Reserves | 24 | 65 | 78 | 465 |
| Borrowings | 69 | 71 | 72 | 133 |
| Other Liabilities | 34 | 45 | 52 | 184 |
| Total Liabilities | 134 | 194 | 215 | 804 |
| Fixed Assets | 44 | 41 | 40 | 43 |
| CWIP | 2 | 0 | 0 | 1 |
| Investments | 0 | 28 | 28 | 158 |
| Other Assets | 88 | 124 | 146 | 602 |
| Total Assets | 134 | 194 | 215 | 804 |
| Category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from Operating Activity | -21 | -4 | 19 | 112 |
| Cash from Investing Activity | -17 | -32 | -13 | -136 |
| Cash from Financing Activity | 30 | 36 | -6 | 433 |
| Net Cash Flow | -8 | -1 | -0 | 409 |
| Free Cash Flow | -38 | -7 | 14 | 105 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -103% | -6% | 77% | 413% |
| Category | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 51.16% | 51.16% | 51.16% |
| FIIs | 5.73% | 4.03% | 2.85% |
| DIIs | 12.86% | 8.52% | 7.83% |
| Public | 30.25% | 36.29% | 38.16% |
| No. of Shareholders | 7,687 | 9,312 | 13,645 |
| Category | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 231 | 272 | 249 | 179 |
| Inventory Days | 83 | 97 | 130 | 208 |
| Days Payable | 140 | 156 | 160 | 89 |
| Cash Conversion Cycle | 174 | 213 | 219 | 298 |
| Working Capital Days | 27 | 70 | 52 | -212 |
| ROCE % | — | 13% | 14% | 7% |
Sai Parenterals Limited
₹2,153Cr.
₹487
₹706/400
86.7
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of SAI PARENTERALS LIMITED (SAIPARENT)?
The reported market capitalisation for SAI PARENTERALS LIMITED (SAIPARENT) is ₹2,153Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of SAIPARENT?
The current price shown for SAI PARENTERALS LIMITED (SAIPARENT) on Fincrux is ₹487 with a 52-week high/low of ₹706/400.
What is the P/E ratio of SAI PARENTERALS LIMITED (SAIPARENT)?
The stock P/E for SAI PARENTERALS LIMITED (SAIPARENT) is 86.7 on Fincrux, with ROE at 5.80% and ROCE at 7.03%.
What were SAIPARENT latest quarterly results?
For Jun 2026, SAI PARENTERALS LIMITED (SAIPARENT) reported sales ₹52.78 Cr and net profit ₹8.88 Cr (figures in ₹ crore unless noted).
What are SAIPARENT annual sales and net profit?
For Mar 2026, SAI PARENTERALS LIMITED (SAIPARENT) shows sales of ₹166 Cr and net profit of ₹17 Cr on the Fincrux profit & loss statement.
Who owns SAI PARENTERALS LIMITED (SAIPARENT)?
Latest shareholding for SAI PARENTERALS LIMITED (SAIPARENT) on Fincrux: Promoters 51.16% (Sep 2026), FIIs 2.85% (Sep 2026), DIIs 7.83% (Sep 2026), Public 38.16% (Sep 2026), No. of Shareholders 13,645% (Sep 2026).
Where can I find SAI PARENTERALS LIMITED (SAIPARENT) financials?
SAI PARENTERALS LIMITED (SAIPARENT) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show SAIPARENT balance sheet and cash flow?
Yes. The SAI PARENTERALS LIMITED (SAIPARENT) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.